Sutib (50 mg) | ঔষধের দাম ও নির্দেশিকা

ব্যবহার

Sunitinib capsule is indicated in-Gastrointestinal Stromal Tumor (GIST): It is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to Imatinib Mesylate. Advanced Renal Cell Carcinoma (RCC): ... Read moreSunitinib capsule is indicated in-Gastrointestinal Stromal Tumor (GIST): It is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to Imatinib Mesylate. Advanced Renal Cell Carcinoma (RCC): It is indicated for the treatment of advanced renal cell carcinoma. Adjuvant Treatment of Renal Cell Carcinoma (RCC): It is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. Advanced Pancreatic Neuroendocrine Tumors (pNET): It is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

ফার্মাকোলজি

Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.

সেবনবিধি

Recommended Dose for GIST and Advanced RCC: The recommended dose of Sutinib for gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC) is one 50 mg oral dose taken once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2). It may be taken with or without food. Recommended Dose for Adjuvant Treatment of RCC: The recommended dose of Sutinib for the adjuvant treatment of RCC is 50 mg taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2), for nine 6-week cycles. It may be taken with or without food. Recommended Dose for pNET: The recommended dose of Sutinib for pancreatic neuroendocrine tumors (pNET) is 37.5 mg taken orally once daily continuously without a scheduled off-treatment period. It may be taken with or without food.

পার্শ্বপ্রতিক্রিয়া

The most common side effects are: Hepatotoxicity, Cardiovascular Events, QT Interval Prolongation andTorsade de Pointes, Hypertension, Hemorrhagic Events, Tumor Lysis Syndrome (TLS), Thrombotic Microangiopathy, Proteinuria, Dermatologic Toxicities, Thyroid Dysfunction, Hypoglycemia, Osteonecrosis of the Jaw (ONJ), Wound Healing.

গর্ভাবস্থায় ও স্তন্যদানকালে ব্যবহার

It can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform a drug-associated risk. If it is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. There is no information regarding the presence of Sunitinib and its metabolites in human milk. Because of the potential for serious adverse reactions in breastfed infants from Sutinib, a lactating woman should be advised not to breastfeed during treatment with Sutinib and for at least 4 weeks after the last dose.

মাত্রাতিরিক্ত ব্যবহার

Treatment of overdose with Sutinib should be consisted of general supportive measures. There is no specific antidote for overdosage with Sutinib. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage. Cases of accidental overdose have been reported; these cases were associated with adverse reactions consistent with the known safety profile of Sutinib, or without adverse reactions. A case of intentional overdose involving the ingestion of 1500 mg of Sutinib in an attempted suicide was reported without adverse reaction. In nonclinical studies, mortality was observed following as few as 5 daily doses of 500 mg/kg (3000 mg/m2) in rats. At this dose, signs of toxicity included impaired muscle coordination, head shakes, hypoactivity, ocular discharge, piloerection, and gastrointestinal distress. Mortality and similar signs of toxicity were observed at lower doses when administered for longer durations.

সংরক্ষণ

Store at 25°C in a cool and dry place, away from light. Keep out of the reach of children.

বিকল্প ওষুধ

Sutib 50 mg Tablet

ডাক্তারের পরামর্শ